Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H16O2 |
Molecular Weight | 240.297 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2
InChI
InChIKey=NPPJLSILDPVHCM-UHFFFAOYSA-N
InChI=1S/C16H16O2/c1-2-18-16(17)12-13-8-10-15(11-9-13)14-6-4-3-5-7-14/h3-11H,2,12H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2293214Curator's Comment: Description was created using several sources including:
http://adisinsight.springer.com/drugs/800008296; https://www.ncbi.nlm.nih.gov/pubmed/2399865; https://www.ncbi.nlm.nih.gov/pubmed/16256708; https://www.ncbi.nlm.nih.gov/pubmed/1447717; https://www.ncbi.nlm.nih.gov/pubmed/2870154; http://www.kegg.jp/entry/D01675
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2293214
Curator's Comment: Description was created using several sources including:
http://adisinsight.springer.com/drugs/800008296; https://www.ncbi.nlm.nih.gov/pubmed/2399865; https://www.ncbi.nlm.nih.gov/pubmed/16256708; https://www.ncbi.nlm.nih.gov/pubmed/1447717; https://www.ncbi.nlm.nih.gov/pubmed/2870154; http://www.kegg.jp/entry/D01675
Felbinac ethyl ester or ethyl 4-biphenylyl acetate (EBA) is a small molecule drug class of analgesics, antipyretics, nonsteroidal anti-inflammatories, phenylacetates. It is a prodrug of non-steroidal anti-inflammatory drug 4-biphenylylacetic acid (BPAA)- an active metabolite of EBA. The use of EBA instead of free BPAA in the form of lipid microspheres or solubilized in cyclodextrins enhances the anti-inflammatory effects of biphenylylacetic acid. Solubilization of EBA in hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) increases absorption and localized activation of the prodrug metabolic process in the epidermis when applied topically to the skin of rats and mice. Felbinac ethyl ester is a prostaglandin inhibitor. When intravenously administered felbinac ethyl ester incorporated in lipid microsphere at the onset of stone pain or vesical urgency in 54 patients with pain from urinary tract stones and 32 with vesical urgency after an operation on bladder or prostate be was found to be a useful drug for controlling stone pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side affects.
Originator
Sources: http://adisinsight.springer.com/drugs/800008296
Curator's Comment: Developed by Pfizer as a drug for treatment of inflammation and pain
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: 1.00725208E8 Gene Symbol: Ptges2 Sources: http://adisinsight.springer.com/drugs/800008296 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2399865
Unknown
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
26436
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | |||
|
DTXSID3046160
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | |||
|
14062-23-8
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | |||
|
m5255
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000172882
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | |||
|
978ZPS989U
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL413965
Created by
admin on Sat Dec 16 01:37:23 GMT 2023 , Edited by admin on Sat Dec 16 01:37:23 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD